Dr. Roué on the Synergistic Activity With TG-1701, Ublituximab, and Umbralisib in MCL

Gaël Roué, PhD, senior scientist at Vall d'Hebron Institute of Oncology and Idibaps research institute Hospital Clinic Barcelona, discusses the synergistic activity with TG-1701, ublituximab, and umbralisib in ibrutinib-resistant mantle cell lymphoma (MCL) models.

TG-1701, a novel irreversible BTK-specific inhibitor, is currently being evaluated both alone and in combination with the anti-CD20 monoclonal antibody ublituximab and the PI3Kδ/CK1ε inhibitor umbralisib. Investigators are interested in understanding the mechanism action of this combination, says Roué. When this combination is used, there is a nice synergistic activity observed both in vitro and in vivo.

This synergistic activity was likely due to a modulation of the inflammatory microenvironment in the cells, shifting from an inflammatory pro-tumor microenvironment to a pro-inflammatory microenvironment; this allows the immune effectors to enter into the tumors, which could explain why the anti-CD20 antibody is working well in this setting, concludes Roué.